Article | Published:

Orthogonal Cas9 proteins for RNA-guided gene regulation and editing

Nature Methods volume 10, pages 11161121 (2013) | Download Citation

Abstract

The Cas9 protein from the Streptococcus pyogenes CRISPR-Cas acquired immune system has been adapted for both RNA-guided genome editing and gene regulation in a variety of organisms, but it can mediate only a single activity at a time within any given cell. Here we characterize a set of fully orthogonal Cas9 proteins and demonstrate their ability to mediate simultaneous and independently targeted gene regulation and editing in bacteria and in human cells. We find that Cas9 orthologs display consistent patterns in their recognition of target sequences, and we identify an unexpectedly versatile Cas9 protein from Neisseria meningitidis. We provide a basal set of orthogonal RNA-guided proteins for controlling biological systems and establish a general methodology for characterizing additional proteins.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu. Rev. Genet. 45, 273–297 (2011).

  2. 2.

    , & RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331–338 (2012).

  3. 3.

    , , & Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA 109, E2579–E2586 (2012).

  4. 4.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

  5. 5.

    , , & Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013).

  6. 6.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  7. 7.

    et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–394 (2013).

  8. 8.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

  9. 9.

    et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 (2013).

  10. 10.

    , , , & RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233–239 (2013).

  11. 11.

    et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509–1512 (2009).

  12. 12.

    , & ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397–405 (2013).

  13. 13.

    et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851–857 (2009).

  14. 14.

    , & Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 93, 1156–1160 (1996).

  15. 15.

    & A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009).

  16. 16.

    & Gene targeting using zinc finger nucleases. Nat. Biotechnol. 23, 967–973 (2005).

  17. 17.

    et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646–651 (2005).

  18. 18.

    et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).

  19. 19.

    et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).

  20. 20.

    et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 (2013).

  21. 21.

    et al. CRISPR RNA–guided activation of endogenous human genes. Nat. Methods 10.1038/nmeth.2598 (25 July 2013).

  22. 22.

    et al. RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nat. Methods 10.1038/nmeth.2600 (25 July 2013).

  23. 23.

    & Determinants of specificity in two-component signal transduction. Curr. Opin. Microbiol. 16, 156–162 (2013).

  24. 24.

    & The second wave of synthetic biology: from modules to systems. Nat. Rev. Mol. Cell Biol. 10, 410–422 (2009).

  25. 25.

    et al. Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. J. Bacteriol. 190, 1401–1412 (2008).

  26. 26.

    et al. Processing-independent CRISPR RNAs limit natural transformation in Neisseria meningitidis. Mol. Cell 50, 488–503 (2013).

  27. 27.

    et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).

  28. 28.

    et al. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429–7437 (2013).

  29. 29.

    et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011).

  30. 30.

    , , & Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493, 429–432 (2013).

  31. 31.

    et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 33, W526–W531 (2005).

Download references

Acknowledgements

We thank P.B. Stranges for protein alignments and W.L. Chew for helpful discussions. This work was supported by US National Institutes of Health NHGRI grant P50 HG005550, US Department of Energy grant DE-FG02-02ER63445 and the Wyss Institute for Biologically Inspired Engineering.

Author information

Author notes

    • Kevin M Esvelt
    •  & Prashant Mali

    These authors contributed equally to this work.

Affiliations

  1. Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Boston, Massachusetts, USA.

    • Kevin M Esvelt
    • , Jonathan L Braff
    • , Stephanie J Yaung
    •  & George M Church
  2. Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

    • Prashant Mali
    • , Mark Moosburner
    • , Stephanie J Yaung
    •  & George M Church
  3. Program in Medical Engineering & Medical Physics, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Stephanie J Yaung

Authors

  1. Search for Kevin M Esvelt in:

  2. Search for Prashant Mali in:

  3. Search for Jonathan L Braff in:

  4. Search for Mark Moosburner in:

  5. Search for Stephanie J Yaung in:

  6. Search for George M Church in:

Contributions

K.M.E. and P.M. conceived of the study; K.M.E. and P.M. designed the experiments; K.M.E., J.L.B. and S.J.Y. performed experiments in E. coli; J.L.B. wrote analysis software; P.M. and M.M. performed experiments in human cells; K.M.E. and P.M. analyzed results; and K.M.E. and P.M. wrote the manuscript with input from G.M.C.

Competing interests

The authors have filed for patents concerning the use of Cas9 proteins for gene targeting and regulation.

Corresponding author

Correspondence to George M Church.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–7, Supplementary Tables 1–3, Supplementary Notes 1–4 and Supplementary Software 1 and 2

Excel files

  1. 1.

    Supplementary Data

    Depletion tables for candidate NM PAMs, ST1 PAMs and TD PAMs; total MiSeq reads for each library; MiSeq clustering and read summaries; and source data for supplementary figures

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nmeth.2681

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing